PT  - JOURNAL ARTICLE
AU  - Oliver S. Grosser
AU  - Juri Ruf
AU  - Dennis Kupitz
AU  - Annette Pethe
AU  - Gerhard Ulrich
AU  - Philipp Genseke
AU  - Konrad Mohnike
AU  - Maciej Pech
AU  - Wolf S. Richter
AU  - Jens Ricke
AU  - Holger Amthauer
TI  - Pharmacokinetics of <sup>99m</sup>Tc-MAA- and <sup>99m</sup>Tc-HSA-Microspheres Used in Preradioembolization Dosimetry: Influence on the Liver–Lung Shunt
AID  - 10.2967/jnumed.115.169987
DP  - 2016 Jun 01
TA  - Journal of Nuclear Medicine
PG  - 925--927
VI  - 57
IP  - 6
4099  - http://jnm.snmjournals.org/content/57/6/925.short
4100  - http://jnm.snmjournals.org/content/57/6/925.full
SO  - J Nucl Med2016 Jun 01; 57
AB  - Perfusion scintigraphy using 99mTc-labeled albumin aggregates is mandatory before hepatic radioembolization with 90Y-microspheres. As part of a prospective trial, the intrahepatic and intrapulmonary stability of 2 albumin compounds, 99mTc-MAA (macroaggregated serum albumin [MAA]) and 99mTc-HSA (human serum albumin [HSA]), was assessed. Methods: In 24 patients with metastatic colorectal cancer, biodistribution (liver, lung) and liver–lung shunt (LLS) of both tracers (12 patients each) were assessed by sequential planar scintigraphy (1, 5, and 24 h after injection). Results: Liver uptake of both albumin compounds decreased differently. Although initial LLSs at 1 h after injection were similar in both groups, MAA-LLS increased significantly from 1 (3.9%) to 5 h (7.7%) and 24 h (9.9%) after injection, respectively. HSA-LLS did not change significantly (1 to 5 h), indicating a steady state of pulmonary and intrahepatic degradation. Conclusion: Compared with 99mTc-MAA-microspheres, 99mTc-HSA-microspheres are likely more resistant to degradation over time, allowing a reliable LLS determination even at later time points.